Passage Bio FY2025 EPS Estimate Lowered by Chardan Capital

Passage Bio, Inc. (NASDAQ:PASG) – Stock analysts at Chardan Capital decreased their FY2025 earnings per share (EPS) estimates for shares of Passage Bio in a research note issued on Wednesday, November 12th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings per share of ($13.31) for the year, down from their prior forecast of ($6.40). Chardan Capital currently has a “Buy” rating and a $21.00 price target on the stock. The consensus estimate for Passage Bio’s current full-year earnings is ($1.03) per share.

Passage Bio (NASDAQ:PASG) last announced its quarterly earnings results on Monday, November 10th. The company reported ($2.44) EPS for the quarter, beating analysts’ consensus estimates of ($2.64) by $0.20.

A number of other research firms have also weighed in on PASG. Weiss Ratings restated a “sell (e+)” rating on shares of Passage Bio in a report on Wednesday, October 8th. Canaccord Genuity Group decreased their price objective on Passage Bio from $260.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, August 14th. Wedbush raised their target price on Passage Bio to $40.00 and gave the company an “outperform” rating in a report on Wednesday, August 13th. Finally, Wall Street Zen raised Passage Bio to a “hold” rating in a research report on Friday, September 5th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Passage Bio presently has an average rating of “Moderate Buy” and a consensus price target of $42.67.

Passage Bio Price Performance

Shares of NASDAQ PASG opened at $8.98 on Monday. The stock has a market capitalization of $28.56 million, a P/E ratio of -0.62 and a beta of 1.94. The company has a 50-day moving average price of $7.74 and a 200-day moving average price of $7.36. Passage Bio has a 1 year low of $5.12 and a 1 year high of $26.60.

Insider Activity at Passage Bio

In other Passage Bio news, major shareholder Lynx1 Capital Management Lp purchased 11,900 shares of the firm’s stock in a transaction that occurred on Monday, September 15th. The stock was bought at an average cost of $6.99 per share, with a total value of $83,181.00. Following the completion of the transaction, the insider owned 623,704 shares of the company’s stock, valued at $4,359,690.96. The trade was a 1.95% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders purchased 32,008 shares of company stock worth $223,726 over the last three months. Company insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Passage Bio stock. Simplex Trading LLC grew its holdings in shares of Passage Bio, Inc. (NASDAQ:PASG) by 9,311.0% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 82,346 shares of the company’s stock after purchasing an additional 81,471 shares during the quarter. Simplex Trading LLC owned approximately 0.13% of Passage Bio worth $29,000 at the end of the most recent reporting period. 53.48% of the stock is owned by institutional investors.

Passage Bio Company Profile

Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.